Refeyn Announces Leadership Transition
Jonathan Flint Steps Down as Chairman, Jean-Paul Mangeolle Appointed as Successor
Advertisement
Refeyn announced that Jonathan Flint is stepping down as Chairman of the Board of Directors after completing two successful three-year terms. Flint’s tenure has been marked by significant growth and innovation, and the company extends its deepest gratitude for his exceptional leadership and dedication.
Jean-Paul Mangeolle - Refeyn’s new Chairman
Refeyn Ltd.
Under Flint’s guidance, Refeyn has achieved major milestones, expanded its global footprint, and strengthened its position as a pioneer in the life sciences industry. His strategic vision and commitment have been instrumental in shaping the company’s success.
Jean-Paul Mangeolle, who has been a member of Refeyn’s Board since August 2022, will assume the role of Chairman with immediate effect. Mangeolle brings over 35 years of experience in the life sciences instruments sector. He most recently served as President of Sciex, an operating company of Danaher Corporation, until his retirement. His deep industry knowledge and leadership experience make him ideally suited to guide Refeyn through its next phase of growth.
"We are incredibly grateful to Jonathan for his outstanding leadership and unwavering support over the past six years. His contributions have been foundational to Refeyn’s success." Gerry MacKay, CEO, commented. "We are equally excited to welcome Jean-Paul as our new Chairman. His extensive experience and strategic insight will be invaluable as we continue to scale our business."
Other news from the department people
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Joachim Kreuzburg, Former CEO of Sartorius, Joins Cube Biotech’s Board of Directors
New high-tech startup developing smart contact lenses for glaucoma diagnosis and management
Insilico Medicine brings AI-powered “ChatPandaGPT” to its target discovery platform - A revolution in drug discovery thanks to a new chat assistant?
Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”
Waters Corporation and Princeton University Announce Multi-Year Research Collaboration - Agreement to take on real-world challenges in biologics and materials research
New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments
CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines - Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma - First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
First-of-its-kind vaccine expands malaria protection for pregnant women - Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years
Siegfried opens new global R&D Center for Drug Substances in Evionnaz - New facility to drive development excellence and further growth
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery - First successful simultaneous 10-target multiplex-screening
